1321518-06-2 Usage
Uses
Used in Pharmaceutical Industry:
2-Bromo-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is used as a synthetic intermediate for the development of pharmaceutical compounds. Its unique structure allows for the creation of diverse drug candidates with potential therapeutic applications, leveraging the compound's reactivity in cross-coupling reactions to introduce novel functionalities into drug molecules.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Bromo-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine serves as a key building block for the assembly of complex organic molecules. Its ability to participate in Suzuki-Miyaura cross-coupling reactions enables chemists to construct intricate molecular architectures with precision, contributing to the advancement of materials science and the discovery of new chemical entities.
Used in Chemical Research:
2-Bromo-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is utilized as a research tool in academic and industrial laboratories. Its involvement in cross-coupling reactions provides insights into reaction mechanisms, catalyst development, and the exploration of new synthetic methodologies, thereby advancing the frontiers of chemical science.
Check Digit Verification of cas no
The CAS Registry Mumber 1321518-06-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,2,1,5,1 and 8 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1321518-06:
(9*1)+(8*3)+(7*2)+(6*1)+(5*5)+(4*1)+(3*8)+(2*0)+(1*6)=112
112 % 10 = 2
So 1321518-06-2 is a valid CAS Registry Number.
1321518-06-2Relevant articles and documents
1,2,4-TRIAZINE-4-AMINE DERIVATIVES
-
Page/Page column 116, (2011/09/14)
According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.